x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

AstraZeneca suspends leading Covid-19 vaccine trials after a participant's illness

Health & Science - By Reuters | September 9th 2020 at 08:29:48 GMT +0300

AstraZeneca Plc said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.

The vaccine, developed with the University of Oxford, has been described by the World Health Organization as probably the world’s leading candidate and the most advanced in terms of development. The suspension dims prospects for an early rollout amid reports that the United States was aiming for a fast-track approval before the November presidential election.

The British drugmaker said it voluntarily paused trials to allow an independent committee to review safety data, and it was working to expedite the review to minimise any potential impact on the trial timeline.

“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials,” the company said in an emailed statement.

Covid 19 Time Series

 

The nature of the illness was not disclosed, although the participant is expected to recover, according to Stat News, which first reported the suspension due to a “suspected serious adverse reaction”.

The U.S. Food and Drug Administration defines an adverse event as one in which evidence suggests a possible relationship to the drug being tested.

According to a New York Times report which cited a person familiar with the situation, a participant based in the United Kingdom was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.

Whether the illness was directly linked to AstraZeneca’s vaccine remains unclear, the report said. AstraZeneca declined to comment on the report.

Shares slide

AstraZeneca’s shares fell more than 8% in after-hours U.S. trading, while shares in rival vaccine developer Moderna Inc rose more than 4%. Shares in AstraZeneca’s Indian unit, AstraZeneca Pharma India Ltd, tumbled more than 12%.

Called AZD1222, the vaccine is in late-stage clinical trials in the United States, Britain, Brazil and South Africa and additional trials are planned in Japan and Russia. The trials aim to enroll up to 50,000 participants globally.

South Korea said on Wednesday it would look into the suspension and review its plan to participate in the manufacturing of the vaccine.

“It’s not rare that clinical trials get suspended as various factors interact,” health ministry official Yoon Tae-ho told a briefing.

The decision to put the trial on hold has impacted clinical trials being conducted by other vaccine makers, which are looking for signs of similar reactions, Stat said.

The U.S. National Institutes of Health, which is providing funding for AstraZeneca’s trial, declined to comment.

Moderna said in an emailed statement it was “not aware of any impact” to its ongoing COVID-19 vaccine study at this time.

Nine leading U.S. and European vaccine developers pledged on Tuesday to uphold scientific safety and efficacy standards for their experimental vaccines despite the urgency to contain the coronavirus pandemic.

The companies, including AstraZeneca, Moderna and Pfizer, issued what they called a “historic pledge” after a rise in concern that safety standards might slip in the face of political pressure to rush out a vaccine.

The companies said they would “uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.”

The other signatories were Johnson & Johnson, Merck & Co, GlaxoSmithKline, Novavax Inc, Sanofi and BioNTech.

Top Stories

How Covid-19 destroys the lung
Health & Science - By Graham Kajilwa


MP’s battle with Covid-19 at home
Health & Science - By Mercy Kahenda


When should a person be pronounced dead?
Health & Science - By Graham Kajilwa


Our clotting disease triggered by the sun
Health & Science - By Mactilda Mbenywe


Blow for Kenyan doctors as court dismiss case to stop foreign doctors
Health & Science - By Paul Ogemba


Covid vaccines: Why the safety process reassures experts
Health & Science - By AFP


Africa lacks preparedness for virus vaccine roll-out: WHO
Health & Science - By AFP


Covid-19: Kagwe warns those using fake certificates as country records 1,554 new cases
Health & Science - By Vincent Kejitan


Uhuru’s Sh930 billion kitty to fight Covid-19
Health & Science - By Dominic Omondi


810 new Covid-19 cases as Kenya inches towards 80,000
Health & Science - By Judah Ben-Hur


Latest Stories

How Covid-19 destroys the lung
Health & Science - By Graham Kajilwa


Covid-19: Kenya records 949 new infections and four deaths
Health & Science - By Vincent Kejitan


Egyptian inventor trials robot that can test for Covid-19
Health & Science - By Reuters


Covid vaccines: Why the safety process reassures experts
Health & Science - By AFP


Counties haven't received Covid funds for 3 months, says Ongwae
Health & Science - By Graham Kajilwa


Uhuru’s Sh930 billion kitty to fight Covid-19
Health & Science - By Dominic Omondi


Blow for Kenyan doctors as court dismiss case to stop foreign doctors
Health & Science - By Paul Ogemba


Africa lacks preparedness for virus vaccine roll-out: WHO
Health & Science - By AFP


Covid-19: Kagwe warns those using fake certificates as country records 1,554 new cases
Health & Science - By Vincent Kejitan


Parliament orders release of sh500 million for healthcare workers medical cover
Health & Science - By Graham Kajilwa


//

Stay Ahead!

Access premium content only available
to our subscribers.

Support independent journalism
×
Log in
Support independent journalism
Create an account    Forgot Password
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in